+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Immune-Mediated Inflammatory Diseases Treatment Market 2019-2025

  • PDF Icon

    Report

  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129625
UP TO OFF until Dec 31st 2022
Global Immune-Mediated Inflammatory Diseases Treatment Market Size, Share & Trends Analysis Report By Disease Type (Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease, Psoriasis, Rheumatoid Arthritis, and Others), By Drug Class (Anti-Inflammatory Biologics, Non- Steroidal Anti- Inflammatory Drugs, Corticosteroids, and Others), By Treatment Type (Targeted Biologic Therapies and Novel Therapies) forecast period (2019-2025)
The global immune-mediated inflammatory disease treatment market is estimated to grow significantly during the forecast period. The market growth is attributed to the increasing cases of immune-mediated inflammatory diseases such as inflammatory bowel disease, psoriasis, rheumatoid arthritis, and others across the globe. In addition, increasing R&D activities by the pharmaceutical players in the industry for the development of novel treatment for immune-mediated inflammatory disease further give a boost to the growth of the market.

The immune-mediated inflammatory disease treatment market is segmented on the basis of disease type, drug class, and treatment type. Based on disease type, the market is sub-segmented into multiple sclerosis, psoriasis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and others. Psoriasis is a genetic condition that may not be present at birth. Changing lifestyles of people are leading to increased alcohol consumption and smoking and an unhealthy diet which makes people more prone to psoriasis. Based on the drug class, the market is segmented into anti-inflammatory biologics, non- steroidal anti-inflammatory drugs, corticosteroids, and others. Based on treatment type, the market is bifurcated into targeted biologic therapies and novel therapies.

Moreover, the study of the global immune-mediated inflammatory disease treatment market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. North America is estimated to hold a prominent share in the market. The region has a well-established healthcare infrastructure that drives the regional growth of the market. Further, Asia-Pacific is estimated to exhibit a considerable CAGR during the forecast period.

Moreover, the study of the report covers the analysis of various players operating in the market. Some of the key players covered in the report include Abbvie Inc., AstraZeneca PLC, Bristol Myers Squibb Co., Pfizer Inc., Amgen Inc., GlaxoSmithKline PLC, Eli Lilly and Co., F. Hoffmann-La Roche AG, Daiichi Sankyo Co. Ltd., Gilead Sciences, Inc., Novartis International AG, and others. These players adopt various organic and inorganic growth strategies to sustain in the competitive market.

Research Methodology

The market study of the immune-mediated inflammatory disease treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for the pharmaceutical industry, healthcare industry, drug manufacturers, clinical-stage companies, research organizations, academic institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future growth opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Immune-Mediated Inflammatory Disease Treatment Market Research and Analysis by Disease Type
2. Global Immune-Mediated Inflammatory Disease Treatment Market Research and Analysis by Therapy
3. Global Immune-Mediated Inflammatory Disease Treatment Market Research and Analysis by Treatment Type

The Report Covers
  • Comprehensive research methodology of the Immune-Mediated Inflammatory Disease Treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Immune-Mediated Inflammatory Disease Treatment market.
  • Insights about market determinants which are stimulating the Immune-Mediated Inflammatory Disease Treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AstraZeneca PLC
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Amgen Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. AbbVie Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. GlaxoSmithKline PLC
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Bristol-Myers Squibb Co.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Immune-Mediated Inflammatory Diseases Treatment Market by Disease Type
5.1.1. Multiple Sclerosis
5.1.2. Psoriasis
5.1.3. Inflammatory Bowel Disease
5.1.4. Rheumatoid Arthritis
5.1.5. Others
5.2. Global immune-Mediated inflammatory diseases treatment Market by Drug Class
5.2.1. Anti- Inflammatory Biologics
5.2.2. Non- Steroidal Anti- Inflammatory Drugs
5.2.3. Corticosteroids
5.3. Global immune-Mediated inflammatory diseases treatment Market by Treatment Type
5.3.1. Targeted Biologic Therapies
5.3.2. Novel Therapies
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbvie Inc.
7.2. Abivax SA
7.3. AstraZeneca PLC
7.4. Boehringer Ingelheim International GmbH
7.5. Bristol-Myers Squibb Co.
7.6. Celgene Corp.
7.7. Daiichi Sankyo Co., Ltd.
7.8. Eli Lilly and Co.
7.9. F. Hoffmann-La Roche Ltd.
7.10. Gilead Sciences, Inc.
7.11. GlaxoSmithKline PLC
7.12. Innovate Biopharmaceuticals Inc.
7.13. Johnson & Johnson Services Inc.
7.14. LG Chem Ltd.
7.15. Merck & Co., Inc.
7.16. Merck KGaA
7.17. Novartis International AG
7.18. Pharmaxis Ltd.
7.19. Sanofi S.A.
7.20. UCB S.A.
7.21. Ventria Bioscience Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbvie Inc.
  • Abivax SA
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Innovate Biopharmaceuticals Inc.
  • Johnson & Johnson Services Inc.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis International AG
  • Pharmaxis Ltd.
  • Sanofi S.A.
  • UCB S.A.
  • Ventria Bioscience Inc.